Liver Gene Therapy in Fabry Disease Mice With Low Doses of rAAV2 /8 Expressing a Codon‐Optimized h GLA cDNA Results in Long‐Term Disease Correction
Journal of Inherited Metabolic Disease · 2026-05 · 49 (3)
DOI: 10.1002/jimd.70188 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Inherited Metabolic Disease, online erschienen am 27.04.2026. Verfasst von Himanshi Saxena und 11 weiteren Autor:innen. Beteiligte Einrichtung: International Centre for Genetic Engineering and Biotechnology, Trieste, Italy. Hauptthemen laut MEDLINE: Fabry Disease, Genetic Therapy, alpha-Galactosidase, Liver. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fondazione Telethon.
Abstract (Originalsprache)
Fabry disease (FD) is an X‐linked lysosomal storage disorder caused by mutations in the GLA gene, which encodes for Alpha Galactosidase‐A (α‐Gal A). α‐Gal A deficiency leads to glycosphingolipid accumulation, like globotriaosylceramide (Gb3) and its deacylated form, globotriaosylsphingosine (lyso‐Gb3), resulting in systemic symptoms and reduced lifespan. Current treatments such as enzyme replacement therapy (ERT) and chaperone therapy are noncurative and have limitations. Gene therapy is an interesting alternative approach that may overcome most of these limitations, and different approaches are currently being tested. Here, we developed a gene therapy approach using rAAV2/8 vectors, delivered intravenously, that target the liver to produce and secrete functional α‐Gal A into circulation. This enzyme is then captured by organs expressing mannose‐6‐phosphate receptors, reducing glycosphingolipid accumulation in affected tissues. We generated a codon‐optimized GLA cDNA with enhanced translatability that was expressed under a strong liver‐specific promoter. In a dose escalation study in juvenile Gla knock‐out (ko) mice, the lowest dose (3.0E11vg/kg) resulted in 85%–95% clearance of lyso‐Gb3 in plasma and tissues, while doses of 3.0E12 vg/kg and higher showed 98%–100% clearance of the glycosphingolipid. All AAV doses were more effective than systemic α‐Gal A administration (ERT). Long‐term treatment showed normal levels of lyso‐Gb3 in plasma and tissues, and corrected neuropathic involvement, as shown in the hot plate test. This study provides a proof‐of‐concept showing that the tested liver‐specific gene therapy vector is capable of preventing disease progression in juvenile Fabry mice at relatively low doses and shows potential in treating both early‐ and late‐onset FD in patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- International Centre for Genetic Engineering and Biotechnology, Trieste, Italy.
- Institute of Clinical Pathology, Department of Laboratory Medicine, University Hospital of Udine, Udine, Italy.
- Regional Coordinator Centre for Rare Diseases, University Hospital of Udine, Udine, Italy.
ORCID-Profile: Andrea Dardis, Andrés F Muro
Förderung
- Fondazione Telethon
Zitieren
APA
Saxena, H., Domenis, R., Romano, G., Biasizzo, J., Ferro, M., Ferino, D., Vicidomini, A., Iaconcig, A., Bortolussi, G., Zentilin, L., Dardis, A., & Muro, A. F. (2026). Liver Gene Therapy in Fabry Disease Mice With Low Doses of rAAV2 /8 Expressing a Codon‐Optimized h GLA cDNA Results in Long‐Term Disease Correction. Journal of Inherited Metabolic Disease, 49(3). https://doi.org/10.1002/jimd.70188
Vancouver
Saxena H, Domenis R, Romano G, Biasizzo J, Ferro M, Ferino D, et al. Liver Gene Therapy in Fabry Disease Mice With Low Doses of rAAV2 /8 Expressing a Codon‐Optimized h GLA cDNA Results in Long‐Term Disease Correction. Journal of Inherited Metabolic Disease. 2026;49(3). doi:10.1002/jimd.70188
BibTeX
@article{Saxena2026,
author = {Saxena, Himanshi and Domenis, Rossana and Romano, Giulia and Biasizzo, Jessica and Ferro, Martina and Ferino, Dania and Vicidomini, Antonio and Iaconcig, Alessandra and Bortolussi, Giulia and Zentilin, Lorena and Dardis, Andrea and Muro, Andrés F},
title = {Liver Gene Therapy in Fabry Disease Mice With Low Doses of rAAV2 /8 Expressing a Codon‐Optimized h GLA cDNA Results in Long‐Term Disease Correction},
journal = {Journal of Inherited Metabolic Disease},
year = {2026},
volume = {49},
number = {3},
doi = {10.1002/jimd.70188}
}
EUVIMED